相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
Sherene Loi et al.
NPJ BREAST CANCER (2022)
CD155: A Key Receptor Playing Diversified Roles
Shyam Sundar Nandi et al.
CURRENT MOLECULAR MEDICINE (2022)
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Eugene Y. Chiang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis
Dan Zhang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2022)
Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
Florence Boissiere-Michot et al.
FRONTIERS IN IMMUNOLOGY (2022)
CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer
Ilaria Magagna et al.
CANCERS (2021)
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
Monika Graeser et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial
Alex De Caluwe et al.
BMC CANCER (2021)
Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
Katsuhiro Yoshikawa et al.
PLOS ONE (2021)
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Gizem Oner et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2021)
High expression of soluble CD155 in estrogen receptor-negative breast cancer
Akiko Iguchi-Manaka et al.
BREAST CANCER (2020)
TIGIT as an emerging immune checkpoint
H. Harjunpaa et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
CD155: A Multi-Functional Molecule in Tumor Progression
Rosa Molfetta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer
Bruna Cerbelli et al.
VIRCHOWS ARCHIV (2020)
Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study
Yu-Chen Li et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
CD155 expression and its prognostic value in postoperative patients with breast cancer
Hongmei Yong et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration
Hana Triki et al.
LIFE SCIENCES (2019)
Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma
Xiangguo Duan et al.
MOLECULAR MEDICINE REPORTS (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Hauke Stamm et al.
ONCOIMMUNOLOGY (2019)
Targeting PVR (CD155) and its receptors in anti-tumor therapy
Paola Kucan Brlic et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy
Xin Chen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers
Tao Jiang et al.
BMC CANCER (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Targeting adenosine for cancer immunotherapy
Robert D. Leone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer
Hauke Stamm et al.
MAMMALIAN GENOME (2018)
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial
L. Buisseret et al.
ANNALS OF ONCOLOGY (2018)
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
Bertrand Allard et al.
IMMUNOLOGICAL REVIEWS (2017)
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
William C. Dougall et al.
IMMUNOLOGICAL REVIEWS (2017)
Targeting A2 adenosine receptors in cancer
David Allard et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Poliovirus Receptor: More than a simple viral receptor
Jonathan R. Bowers et al.
VIRUS RESEARCH (2017)
Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review
Rong Wang et al.
ONCOTARGET (2017)
CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer
Weiling He et al.
CANCER RESEARCH (2017)
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions
Feng Xu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
CD73-adenosine: a next-generation target in immuno-oncology
David Allard et al.
IMMUNOTHERAPY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Purinergic regulation of the immune system
Caglar Cekic et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities
Luca Antonioli et al.
TRENDS IN CANCER (2016)
Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma
Valentina Bevelacqua et al.
Oncotarget (2015)
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
The Roles of CD73 in Cancer
Zhao-wei Gao et al.
BIOMED RESEARCH INTERNATIONAL (2014)
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Sherene Loi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network
Nancy U. Lin et al.
CANCER (2012)
The role of nectins in different types of cell-cell adhesion
Yoshiyuki Rikitake et al.
JOURNAL OF CELL SCIENCE (2012)
CD73 Expression as a Potential Marker of Good Prognosis in Breast Carcinoma
Anna Supernat et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2012)
Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma
Reiko Nakai et al.
CANCER SCIENCE (2010)
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
Silvia Deaglio et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Overexpression of the CD155 gene in human colorectal carcinoma
D Masson et al.
GUT (2001)
分享论文
